In a recent study, patients with unresectable HCC underwent immunotherapy regimens of anti-angiogenic kinase inhibitors (lenvatinib or apatinib) in combination with anti-PD1 antibodies (nivolumab, pembrolizumab, sintilimab, or camrelizumab), and 16% of the patients successfully achieved eligibility and were surgically treated [28]. Here, PDCD1 is linked to hepatocellular carcinoma.